REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone240-552-8181
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$218.51 million
Profitability
Miscellaneous
Employees192
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Regenxbio (NASDAQ:RGNX) Frequently Asked Questions
What is Regenxbio's stock symbol?
Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."
How were Regenxbio's earnings last quarter?
Regenxbio Inc (NASDAQ:RGNX) posted its earnings results on Wednesday, August, 7th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.46. The biotechnology company had revenue of $7.88 million for the quarter, compared to the consensus estimate of $5.45 million. Regenxbio had a negative return on equity of 15.39% and a negative net margin of 88.57%. The business's quarterly revenue was down 80.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.30 earnings per share. View Regenxbio's Earnings History.
When is Regenxbio's next earnings date?
What price target have analysts set for RGNX?
8 analysts have issued 12 month price objectives for Regenxbio's shares. Their predictions range from $37.00 to $150.00. On average, they expect Regenxbio's share price to reach $82.25 in the next twelve months. This suggests a possible upside of 142.4% from the stock's current price. View Analyst Price Targets for Regenxbio.
What is the consensus analysts' recommendation for Regenxbio?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Regenxbio.
What are Wall Street analysts saying about Regenxbio stock?
Here are some recent quotes from research analysts about Regenxbio stock:
- 1. According to Zacks Investment Research, "REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. " (7/25/2019)
- 2. Chardan Capital analysts commented, "We note Sarepta Therapeutics (unrated) may be relevant for that theme. The IP discussion began by REGENXBIO discussing Zolgensma and the agreement with Avexis, a Novartis (unrated) company, where REGENXBIO will receive tiered royalties of 6%, 8%, and 10% on Zolgensma sales of $600 mm, respectively, as well as a milestone payment of $80 mm once Zolgensma reaches $1 bn in aggregate sales." (6/18/2019)
Has Regenxbio been receiving favorable news coverage?
Media stories about RGNX stock have been trending positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Regenxbio earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the near term. View News Stories for Regenxbio.
Who are some of Regenxbio's key competitors?
Some companies that are related to Regenxbio include Repligen (RGEN), Moderna (MRNA), argenx (ARGX), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD) and Sangamo Therapeutics (SGMO).
What other stocks do shareholders of Regenxbio own?
Who are Regenxbio's key executives?
Regenxbio's management team includes the folowing people:
- Mr. Kenneth T. Mills, CEO, Pres & Director (Age 44)
- Mr. Vittal K. Vasista, Chief Financial Officer (Age 51)
- Mr. Curran M. Simpson, Sr. VP of Product Devel. & Chief Technology Officer (Age 57)
- Dr. Olivier Danos, Chief Scientific Officer (Age 61)
- Dr. Stephen Yoo, Consultant (Age 41)
Who are Regenxbio's major shareholders?
Regenxbio's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (13.71%), BlackRock Inc. (13.71%), Vanguard Group Inc. (9.37%), JPMorgan Chase & Co. (3.23%), Perceptive Advisors LLC (2.64%) and Price T Rowe Associates Inc. MD (1.80%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for Regenxbio.
Which institutional investors are selling Regenxbio stock?
RGNX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Invesco Ltd., Perceptive Advisors LLC, SG Americas Securities LLC, Bank of New York Mellon Corp, AQR Capital Management LLC, Acadian Asset Management LLC and Price T Rowe Associates Inc. MD. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Insider Buying and Selling for Regenxbio.
Which institutional investors are buying Regenxbio stock?
RGNX stock was purchased by a variety of institutional investors in the last quarter, including Korea Investment CORP, UBS Group AG, Hillhouse Capital Advisors LTD., Nuveen Asset Management LLC, Morgan Stanley, BlackRock Inc., BlackRock Inc. and Balyasny Asset Management LLC. View Insider Buying and Selling for Regenxbio.
How do I buy shares of Regenxbio?
Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Regenxbio's stock price today?
One share of RGNX stock can currently be purchased for approximately $33.93.
How big of a company is Regenxbio?
Regenxbio has a market capitalization of $1.25 billion and generates $218.51 million in revenue each year. The biotechnology company earns $99.94 million in net income (profit) each year or $2.38 on an earnings per share basis. Regenxbio employs 192 workers across the globe.View Additional Information About Regenxbio.
What is Regenxbio's official website?
How can I contact Regenxbio?
Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]
MarketBeat Community Rating for Regenxbio (NASDAQ RGNX)
MarketBeat's community ratings are surveys of what our community members think about Regenxbio and other stocks. Vote "Outperform" if you believe RGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
